Description:
Pilaralisib is a Class 1 phosphatidylinositol 3 kinase (PI3K) family inhibitor. It is an orally bioavailable small molecule, targeting the class I PI3K family of lipid kinases. It is a pyrimidine derivatives compound discovered by Exelixis Inc. It has potential antineoplastic activity. It binds to class 1 PI3Ks in an ATP-competitive manner by inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and inhibiting the activation of the PI3K signaling pathway.
- Molecular Weight:448.52
- Boiling Point:638.9±65.0 °C | Condition: Press: 760 Torr
- Purity:>99%
Molecular Formula:
C21H16N6O2S2
Canonical SMILES:
CC1=CC=C(C=C1)S(=O)(=O)NC2=NC3=CC=CC=C3N=C2NC4=CC5=NSN=C5C=C4
InChI:
InChI=1S/C21H16N6O2S2/c1-13-6-9-15(10-7-13)31(28,29)27-21-20(23-16-4-2-3-5-17(16)24-21)22-14-8-11-18-19(12-14)26-30-25-18/h2-12H,1H3,(H,22,23)(H,24,27)
InChIKey:
MQMKRQLTIWPEDM-UHFFFAOYSA-N
Solubility:
DMSO ≥86mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL
Appearance:
White to off-white Solid
Application:
Pilaralisib has potential antineoplastic activity.
Storage: -20°C Freezer
Synonyms:
XL147-II; XL147 II; XL147II; XL147 derivative II; XL147derivativeII; XL147-derivative-II; N-[3-(2,1,3-Benzothiadiazol-5-ylamino)-2-quinoxalinyl]-4-methylbenzenesulfonamide;SAR245408;N-[3-(Benzo[c][1,2,5]thiadiazol-5-ylaMino)quinoxalin-2-yl]-4-MethylbenzenesulfonaMide;PI3K inhibitorX Weitere Informationen finden Sie
hier